Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

Summary

This study will evaluate the efficacy and safety of zodasiran subcutaneous (sc) injection in participants 12 to \<18 years of age with genetically or clinically diagnosed homozygous familial hypercholesterolemia (HoFH) and low-density lipoprotein cholesterol (LDL-C) ≥116 milligrams per deciliter (mg/dL) on maximally tolerated lipid-lowering therapy.

Timeline

Start

2026-08

Primary completion

2028-07

Completion

2028-08

Drugs

Indications